Polmacoxib (trade name Acelex) is a
nonsteroidal anti-inflammatory drug (NSAID) used to treat
osteoarthritis. It was developed as CG100649 and approved for use in South Korea in February 2015.[1] It inhibits the enzymes
carbonic anhydrase and
COX-2.
A study in healthy volunteers showed drug effects on urinary
prostaglandin metabolites for both polmacoxib and
celecoxib that suggest a similar cardiovascular risk profile.[2] Further work by this group developed dose-exposure relationships of polmacoxib to guide clinical development strategies.[3]
^Hirankarn S, Barrett JS, Alamuddin N, FitzGerald GA, Skarke C (October 2013). "GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies". Clinical Pharmacology in Drug Development. 2 (4): 379–86.
doi:
10.1002/cpdd.47.
PMID27121942.
S2CID35992507.